| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,660 | 1,694 | 23.12. | |
| 1,631 | 1,724 | 23.12. |
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Mo | Protalix BioTherapeutics, Inc. - 8-K, Current Report | ||
| 10.12. | EMA validates Chiesi and Protalix's dose variation for Fabry disease | ||
| 09.12. | Chiesi Global, Protalix Announce EMA Validation Of Variation Submission For Pegunigalsidase Alfa | BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Chiesi Global Rare Diseases, a unit of Chiesi Group, and Protalix BioTherapeutics announced the European Medicines Agency has validated the Variation Submission... ► Artikel lesen | |
| 09.12. | Chiesi Global Rare Diseases and Protalix BioTherapeutics, Inc.: Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce Validation of Variation Submission by European Medicines Agency for pegunigalsidase alfa | - Application to label a less frequent dosing regimen at a dose of 2 mg/kg body weight administered every four weeks in adult patients with Fabry disease in European Union
PARMA, Italy... ► Artikel lesen | |
| 15.11. | Protalix BioTherapeutics, Inc. (AMEX:PLX) Q3 2024 Earnings Call Transcript |
| Unternehmen / Aktien | Kurs | % |
|---|---|---|
| PROTALIX BIOTHERAPEUTICS INC | 1,647 | -1,79 % |
